Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma

Clin Infect Dis. 2012 Jan 15;54(2):253-6. doi: 10.1093/cid/cir791. Epub 2011 Nov 17.

Abstract

Twelve trachoma-hyperendemic communities were treated with 3 annual mass azithromycin distributions. Children aged 0-9 years were monitored 1 year following the third treatment. An RNA-based test detected ocular chlamydial infection in more children than did a DNA-based test (6.9% vs 4.2%), and in a larger number of communities (8 vs 7).

Trial registration: ClinicalTrials.gov NCT00322972.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Antibiotic Prophylaxis / methods
  • Azithromycin / administration & dosage*
  • Child
  • Child, Preschool
  • Chlamydia trachomatis / genetics
  • Chlamydia trachomatis / isolation & purification*
  • Ethiopia / epidemiology
  • Female
  • Humans
  • Infant
  • Male
  • Prevalence
  • Preventive Health Services
  • RNA, Bacterial / analysis*
  • RNA, Bacterial / genetics
  • RNA, Ribosomal / analysis*
  • RNA, Ribosomal / genetics
  • Statistics, Nonparametric
  • Trachoma / drug therapy
  • Trachoma / epidemiology
  • Trachoma / microbiology
  • Trachoma / prevention & control*

Substances

  • Anti-Bacterial Agents
  • RNA, Bacterial
  • RNA, Ribosomal
  • Azithromycin

Associated data

  • ClinicalTrials.gov/NCT00322972